Solid lipid nanoparticles for brain tumors therapy: State of the art and novel challenges

Progress in Brain Research

Volumn 180, Issue C, 2009, Pages 193-223

  Brioschi, Andrea M ^a   Calderoni, Sara ^a   Zara, Gian Paolo ^b   Priano, Lorenzo ^a,b   Gasco, Maria Rosa ^c   Mauro, Alessandro ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c NANOVECTOR S R L   (Italy)

Author keywords

Angiogenesis; Brain tumor imaging; Brain tumors; Cholesterylbutyrate; Drug targeting; Solid lipid nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; LIPID; NANOPARTICLE;

ANIMAL; BLOOD BRAIN BARRIER; BRAIN TUMOR; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; NANOTECHNOLOGY; NEUROCHEMISTRY; NEUROPHARMACOLOGY; ONCOLOGY; RAT; REVIEW; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; LIPIDS; MEDICAL ONCOLOGY; NANOPARTICLES; NANOTECHNOLOGY; NEUROCHEMISTRY; NEUROPHARMACOLOGY; RATS;

EID: 77953464955     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)80011-8     Document Type: Article

References (192)

1. Ambruosi, A., Khalansky, A. S., Yamamoto, H., Gelperina, S. E., Begley, D. J., & Kreuter, J. (2006). Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. Journal of Drug Targeting, 14(2), 97-105.
2. Bach Knudsen, K. E., Serena, A., Canibe, N., & Juntunen, K. S. (2003). New insight into butyrate metabolism. The Proceedings of the Nutrition Society, 62(1), 81-86.
3. Balakin, K. V., Ivanenkov, Y. A., Kiselyov, A. S., & Tkachenko, S. E. (2007). Histone deacetylase inhibitors in cancer therapy: Latest developments, trends and medicinal chemistry perspective. Anti-Cancer Agents in Medicinal Chemistry, 7(5), 576-592.
4. Barratt, G. (2003). Colloidal drug carriers: Achievements and perspectives. Cellular andMolecular Life Sciences, 60(1), 21-37.
5. Barth, R. F. (1998). Rat brain tumor models in experimental neuro-oncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. Journal of Neuro-Oncology, 36(1), 91-102.
6. Beduneau, A., Saulnier, P., & Benoit, J. P. (2007). Active targeting of brain tumors using nanocarriers. Biomaterials, 28(33), 4947-4967.
7. Bhalla, K. N. (2005). Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. Journal of Clinical Oncology, 23(17), 3971-3993.
8. Birner, P., Piribauer, M., Fischer, I., Gatterbauer, B., Marosi, C., Ambros, P. F., et al. (2003). Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypes. Brain Pathology, 13(2), 133-143.
9. Blakeley, J. (2008). Drug delivery to brain tumors. Current Neurology and Neuroscience Reports, 8(3), 235-241.
10. Blasi, P., Giovagnoli, S., Schoubben, A., Ricci, M., & Rossi, C. (2007). Solid lipid nanoparticles for targeted brain drug delivery. Advanced Drug Delivery Reviews, 59(6), 454-477.
11. Boado, R. J. (2005). RNA interference and nonviral targeted gene therapy of experimental brain cancer. NeuroRx, 2(1), 139-150.
12. Bocca, C., Caputo, O., Cavalli, R., Gabriel, L., Miglietta, A., & Gasco, M. R. (1998). Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. International Journal of Pharmaceutics, 175, 185-193.
13. Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006). Anticancer activities of histone deacetylase inhibitors. Nature Reviews. Drug Discovery, 5(9), 769-784.
14. Breyer, R., Hussein, S., Radu, D. L., Putz, K. M., Gunia, S., Hecker, H., et al. (2000). Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. Journal of Neurosurgery, 92(1), 140-149.
15. Brioschi, A., Zara, G. P., Calderoni, S., Gasco, M. R., & Mauro, A. (2008). Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules, 13(2), 230-254.
16. Brioschi, A. M., Calderoni, S., Pradotto, L. G., Guido, M., Strada, A., Zenga, F., et al. (2009). Solid lipid nanoparticles carrying oligonucleotides inhibit vascular endothelial growth factor expression in rat glioma models. Journal of Nanoneuroscience, 1(1), 65-74.
17. Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., & Uhm, J. H. (2007). Central nervous system tumors. Mayo Clinic Proceedings, 82(10), 1271-1286.
18. Carpentier, A. F. (2005). Neuro-oncology: The growing role of chemotherapy in glioma. Lancet Neurology, 4(1), 4-5.
19. Carpentier, A. F., & Meng, Y. (2006). Recent advances in immunotherapy for human glioma. Current Opinion in Oncology, 18(6), 631-636.
20. Cavaliere, R., Wen, P. Y., & Schiff, D. (2007). Novel therapies for malignant gliomas. Neurologic Clinics, 25(4), 1141-1171.
21. Cavalli, R., Bargoni, A., Podio, V., Muntoni, E., Zara, G. P., & Gasco, M. R. (2003). Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. Journal Pharmaceutical Sciences, 92(5), 1085-1094.
22. Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005). Micro-RNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Research, 65(14), 6029-6033.
23. Cheepala, S. B., Syed, Z., Trutschl, M., Cvek, U., & Clifford, J. L. (2007). Retinoids and skin: Microarrays shed new light on chemopreventive action of all-trans retinoic acid. Molecular Carcinogenesis, 46(8), 634-639.
24. Chen, D. B., Yang, T. Z., Lu, W. L., & Zhang, Q. (2001). In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chemical & Pharmaceutical Bulletin (Tokyo), 49(11), 1444-1447.
25. Chen, J. S., Faller, D. V., & Spanjaard, R. A. (2003). Shortchain fatty acid inhibitors of histone deacetylases: Promising anticancer therapeutics? Current Cancer Drug Targets, 3(3), 219-236.
26. Chertok, B., David, A. E., Huang, Y., & Yang, V. C. (2007). Glioma selectivity of magnetically targeted nanoparticles: A role of abnormal tumor hydrodynamics. Journal of Controlled Release, 122(3), 315-323.
27. Cho, K., Wang, X., Nie, S., Chen, Z. G., & Shin, D. M. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research, 14(5), 1310-1316.
28. Ciafre, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C. G., Sabatino, G., et al. (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications, 334(4), 1351-1358.
29. Claes, A., Schuuring, J., Boots-Sprenger, S., Hendriks-Cornelissen, S., Dekkers, M., Van Der Kogel, A. J., et al. (2008). Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathology, 18(3), 423-433.
30. Cohen, S. S., Flaks, J. G., Barner, H. D., Loeb, M. R., & Lichtenstein, J. (1958). The mode of action of 5-fluorouracil and its derivatives. Proceedings of the National Academy of Sciences, USA, 44(10), 1004-1012.
31. Conley, B. A., Egorin, M. J., Tait, N., Rosen, D. M., Sausville, E. A., Dover, G., et al. (1998). Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clinical Cancer Research, 4(3), 629-634.
32. Cornic, M., Guidez, F., Delva, L., Agadir, A., Degos, L., & Chomienne, C. (1992). Mechanism of action of retinoids in a new therapeutic approach to acute promyelocytic leukemia. Bulletin du Cancer, 79(7), 697-704.
33. Criniere, E., Kaloshi, G., Laigle-Donadey, F., Lejeune, J., Auger, N., Benouaich-Amiel, A., et al. (2007). MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. Journal of Neuro-Oncology, 83(2), 173-179.
34. Dass, C. R. (2002). Vehicles for oligonucleotide delivery to tumours. The Journal of Pharmacy and Pharmacology, 54(1), 3-27.
35. DeAngelis, L. M. (2001). Brain tumors. The New England Journal of Medicine, 344(2), 114-123.
36. Dehouck, B., Fenart, L., Dehouck, M. P., Pierce, A., Torpier, G., & Cecchelli, R. (1997). A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. The Journal of Cell Biology, 138(4), 877-889.
37. Di Marco, A. (1978). Mechanism of action and mechanism of resistance to antineoplastic agents that bind to DNA. Antibiotics and Chemotherapy, 23, 216-227.
38. Du, H., Sheriff, S., Bezerra, J., Leonova, T., & Grabowski, G. A. (1998). Molecular and enzymatic analyses of lysosomal acid lipase in cholesteryl ester storage disease. Molecular Genetics and Metabolism, 64(2), 126-134.
39. Edetsberger, M., Gaubitzer, E., Valic, E., Waigmann, E., & Kohler, G. (2005). Detection of nanometer-sized particles in living cells using modern fluorescence fluctuation methods. Biochemical and Biophysical Research Communications, 332(1), 109-116.
40. Egorin, M. J., Yuan, Z. M., Sentz, D. L., Plaisance, K., & Eiseman, J. L. (1999). Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemotherapy and Pharmacology, 43(6), 445-453.
41. Entin-Meer, M., Rephaeli, A., Yang, X., Nudelman, A., Nudelman, A., & Haas-Kogan, D. A. (2007). AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Cancer Letters, 253(2), 205-214.
42. Entin-Meer, M., Rephaeli, A., Yang, X., Nudelman, A., VandenBerg, S. R., & Haas-Kogan, D. A. (2005). Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Molecular Cancer Therapeutics, 4(12), 1952-1961.
43. Farhadi, M. R., Capelle, H. H., Erber, R., Ullrich, A., & Vajkoczy, P. (2005). Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: Effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. Journal of Neurosurgery, 102(2), 363-370.
44. Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., et al. (2006a). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the National Academy of Sciences, USA, 103(16), 6315-6320.
45. Farokhzad, O. C., Karp, J. M., & Langer, R. (2006b). Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opinion on Drug Delivery, 3(3), 311-324.
46. Ferrara, N., & Davis-Smyth, T. (1997). The biology of vascular endothelial growth factor. Endocrine Reviews, 18(1), 4-25.
47. Ferrara, N., Gerber, H. P., & LeCouter, J. (2003). The biology of VEGF and its receptors. Nature Medicine, 9(6), 669-676.
48. Fisher, J. L., Schwartzbaum, J. A., Wrensch, M., & Wiemels, J. L. (2007). Epidemiology of brain tumors. Neurologic Clinics, 25(4), 867-890, vii.
49. Fishman, J. B., Rubin, J. B., Handrahan, J. V., Connor, J. R., & Fine, R. E. (1987). Receptor-mediated transcytosis of transferrin across the blood-brain barrier. Journal of Neuroscience Research, 18(2), 299-304.
50. Fomchenko, E. I., & Holland, E. C. (2006). Mouse models of brain tumors and their applications in preclinical trials. Clinical Cancer Research, 12(18), 5288-5297.
51. Friedman, H. S., Kerby, T., & Calvert, H. (2000). Temozolomide and treatment of malignant glioma. Clinical Cancer Research, 6(7), 2585-2597.
52. Fukumura, D., Xu, L., Chen, Y., Gohongi, T., Seed, B., & Jain, R. K. (2001). Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Research, 61(16), 6020-6024.
53. Fundaro, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., & Gasco, M. R. (2000). Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacological Research, 42(4), 337-343.
54. Gaidamakova, E. K., Backer, M. V., & Backer, J. M. (2001). Molecular vehicle for target-mediated delivery of therapeutics and diagnostics. Journal of Controlled Release, 74(1-3), 341-347.
55. Gasco, M. R. (2007). Lipid nanoparticles: Perspectives and challenges. Advanced Drug Delivery Reviews, 59(6), 377-378.
56. Goppert, T. M., & Muller, R. H. (2005). Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. Journal of Drug Targeting, 13(3), 179-187.
57. Gupta, Y., Jain, A., & Jain, S. K. (2007). Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. The Journal of Pharmacy and Pharmacology, 59(7), 935-940.
58. Huang, G., Zhang, N., Bi, X., & Dou, M. (2008). Solid lipid nanoparticles of temozolomide: Potential reduction of cardial and nephric toxicity. International Journal of Pharmaceutics, 355(1-2), 314-320.
59. Jain, K. K. (2007). Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Review of Neurotherapeutics, 7(4), 363-372.
60. Jain, R. K., Di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007). Angiogenesis in brain tumours. Nature Reviews. Neuroscience, 8(8), 610-622.
61. Jain, S. K., Chaurasiya, A., Gupta, Y., Jain, A., Dagur, P., Joshi, B., et al. (2008). Development and characterization of 5-fU bearing ferritin appended solid lipid nanoparticles for tumour targeting. Journal of Microencapsulation, 25(5), 289-297.
62. Jansen, M., De Witt Hamer, P. C., Witmer, A. N., Troost, D., & van Noorden, C. J. (2004). Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Research. Brain Research Reviews, 45(3), 143-163.
63. Jiang, Z., & Sharfstein, S. T. (2008). Sodium butyrate stimulates monoclonal antibody over-expression in CHO cells by improving gene accessibility. Biotechnology and Bioengineering, 100(1), 189-194.
64. Johansson, M., Brannstrom, T., Bergenheim, A. T., & Henriksson, R. (2002). Spatial expression of VEGF-A in human glioma. Journal of Neuro-Oncology, 59(1), 1-6.
65. Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008). Potential of solid lipid nanoparticles in brain targeting. Journal of Controlled Release, 127(2), 97-109.
66. Ke, L. D., Shi, Y. X., Im, S. A., Chen, X., & Yung, W. K. (2000). The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clinical Cancer Research, 6(6), 2562-2572.
67. Ke, L. D., Shi, Y. X., & Yung, W. K. (2002). VEGF(121), VEGF(165) overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells. Cancer Research, 62(6), 1854-1861.
68. Kim, W. J., Yockman, J. W., Lee, M., Jeong, J. H., Kim, Y. H., & Kim, S. W. (2005). Soluble flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. Journal of Controlled Release, 106(1-2), 224-234.
69. Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2003). In situ blood-brain barrier transport of nanoparticles. Pharmaceutical Research, 20(11), 1772-1778.
70. Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2004). Paclitaxel nanoparticles for the potential treatment of brain tumors. Journal of Controlled Release, 99(2), 259-269.
71. Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2006). The blood-brain barrier and brain drug delivery. Journal of Nanoscience and Nanotechnology, 6(9-10), 2712-2735.
72. Kreuter, J. (2001). Nanoparticulate systems for brain delivery of drugs. Advanced Drug Delivery Reviews, 47(1), 65-81.
73. Krum, J. M., & Rosenstein, J. M. (1998). VEGF mRNA and its receptor flt-1 are expressed in reactive astrocytes following neural grafting and tumor cell implantation in the adult CNS. Experimental Neurology, 154(1), 57-65.
74. Krutzfeldt, J., Kuwajima, S., Braich, R., Rajeev, K. G., Pena, J., Tuschl, T., et al. (2007). Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Research, 35(9), 2885-2892.
75. Lai, S. K., Hida, K., Man, S. T., Chen, C., Machamer, C., Schroer, T. A., et al. (2007). Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a nonclathrin, non-degradative pathway. Biomaterials, 28(18), 2876-2884.
76. Lamszus, K., Ulbricht, U., Matschke, J., Brockmann, M. A., Fillbrandt, R., & Westphal, M. (2003). Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clinical Cancer Research, 9(4), 1399-1405.
77. le Sage, C., Nagel, R., Egan, D. A., Schrier, M., Mesman, E., Mangiola, A., et al. (2007). Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. The EMBO Journal, 26(15), 3699-3708.
78. Lee, M. J., Kim, Y. S., Kummar, S., Giaccone, G., & Trepel, J. B. (2008). Histone deacetylase inhibitors in cancer therapy. Current Opinion in Oncology, 20(6), 639-649.
79. Lim, S. J., Lee, M. K., & Kim, C. K. (2004). Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. Journal of Controlled Release, 100(1), 53-61.
80. Liu, X., Fortin, K., & Mourelatos, Z. (2008). MicroRNAs: Biogenesis and molecular functions. Brain Pathology, 18(1), 113-121.
81. Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. Journal of Drug Targeting, 12(9-10), 635-641.
82. Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., et al. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica, 114(2), 97-109.
83. Louis, D. N., Pomeroy, S. L., & Cairncross, J. G. (2002). Focus on central nervous system neoplasia. Cancer Cell, 1(2), 125-128.
84. Lu, W., Zhang, Y., Tan, Y. Z., Hu, K. L., Jiang, X. G., & Fu, S. K. (2005). Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. Journal of Controlled Release, 107(3), 428-448.
85. Maier-Hauff, K., Rothe, R., Scholz, R., Gneveckow, U., Wust, P., Thiesen, B., et al. (2007). Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. Journal of Neuro-Oncology, 81(1), 53-60.
86. Manjunath, K., & Venkateswarlu, V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. Journal of Controlled Release, 107(2), 215-228.
87. Marcato, P. D., & Duran, N. (2008). New aspects of nanopharmaceutical delivery systems. Journal of Nanoscience and Nanotechnology, 8(5), 2216-2229.
88. Martinez-Murillo, R., & Martinez, A. (2007). Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells. Histology and Histopathology, 22(12), 1309-1326.
89. Martin-Villalba, A., Okuducu, A. F., & von Deimling, A. (2008). The evolution of our understanding on glioma. Brain Pathology, 18(3), 455-463.
90. Mathieu, D., Lecomte, R., Tsanaclis, A. M., Larouche, A., & Fortin, D. (2007). Standardization and detailed characterization of the syngeneic Fischer/F98 glioma model. The Canadian Journal of Neurological Sciences, 34(3), 296-306.
91. Mayor, S., & Pagano, R. E. (2007). Pathways of clathrin-independent endocytosis. Nature Reviews. Molecular Cell Biology, 8(8), 603-612.
92. Mehnert, J. M., & Kelly, W. K. (2007). Histone deacetylase inhibitors: Biology and mechanism of action. Cancer Journal, 13(1), 23-29.
93. Mehnert, W., & Mader, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews, 47(2-3), 165-196.
94. Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine, 353(19), 2012-2024.
95. Miglietta, A., Cavalli, R., Bocca, C., Gabriel, L., & Gasco, M. R. (2000). Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. International Journal of Pharmaceutics, 210(1-2), 61-67.
96. Miller, A. A., Kurschel, E., Osieka, R., & Schmidt, C. G. (1987). Clinical pharmacology of sodium butyrate in patients with acute leukemia. European Journal of Cancer & Clinical Oncology, 23(9), 1283-1287.
97. Miller, S. J. (2004). Cellular and physiological effects of shortchain fatty acids. Mini Reviews in Medicinal Chemistry, 4(8), 839-845.
98. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185-229.
99. Minow, R. A., Benjamin, R. S., Lee, E. T., & Gottlieb, J. A. (1977). Adriamycin cardiomyopathy-risk factors. Cancer, 39(4), 1397-1402.
100. Minucci, S., & Pelicci, P. G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews. Cancer, 6(1), 38-51.
101. Mischel, P. S., Shai, R., Shi, T., Horvath, S., Lu, K. V., Choe, G., et al. (2003). Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene, 22(15), 2361-2373.
102. Moffat, B. A., Reddy, G. R., McConville, P., Hall, D. E., Chenevert, T. L., Kopelman, R. R., et al. (2003). A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Molecular Imaging, 2(4), 324-332.
103. Muldoon, L. L., Sandor, M., Pinkston, K. E., & Neuwelt, E. A. (2005). Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery, 57(4), 785-796; discussion 785-796.
104. Muller, R. H., & Keck, C. M. (2004). Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. Journal of Biotechnology, 113(1-3), 151-170.
105. Muller, R. H., Mader, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 161-177.
106. Muller, R. H., & Olbrich, C. (1999). Solid lipid nanoparticles: Phagocytic uptake, in vitro cytotoxicity and in vitro biodegradation. Pharmazeutische Industrie, 61, 564-569.
107. Nicoloso, M. S., & Calin, G. A. (2008). MicroRNA involvement in brain tumors: From bench to bedside. Brain Pathology, 18(1), 122-129.
108. Niola, F., Evangelisti, C., Campagnolo, L., Massalini, S., Bue, M. C., Mangiola, A., et al. (2006). A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biology & Therapy, 5(2), 174-179.
109. Norden, A. D., Drappatz, J., & Wen, P. Y. (2008a). Antiangiogenic therapy in malignant gliomas. Current Opinion in Oncology, 20(6), 652-661.
110. Norden, A. D., Drappatz, J., &Wen, P. Y. (2008b). Novel antiangiogenic therapies for malignant gliomas. Lancet Neurology, 7(12), 1152-1160.
111. Norden, A. D., & Wen, P. Y. (2006). Glioma therapy in adults. Neurologist, 12(6), 279-292.
112. Nudelman, A., Gnizi, E., Katz, Y., Azulai, R., Cohen-Ohana, M., Zhuk, R., et al. (2001). Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. European Journal of Medicinal Chemistry, 36(1), 63-74.
113. O'Dwyer, P. J., & Catalano, R. B. (2006). Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: Practical pharmacogenomics arrives in cancer therapy. Journal of Clinical Oncology, 24(28), 4534-4538.
114. Olbrich, C., Bakowsky, U., Lehr, C. M., Muller, R. H., & Kneuer, C. (2001). Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. Journal of Controlled Release, 77(3), 345-355.
115. Pardridge, W. M. (2007). Drug targeting to the brain. Pharmaceutical Research, 24(9), 1733-1744.
116. Partlow, K. C., Lanza, G. M., &Wickline, S. A. (2008). Exploiting lipid raft transport with membrane targeted nanoparticles: A strategy for cytosolic drug delivery. Biomaterials, 29(23), 3367-3375.
117. Parveen, S., & Sahoo, S. K. (2008). Polymeric nanoparticles for cancer therapy. Journal of Drug Targeting, 16(2), 108-123.
118. Patnaik, A., Rowinsky, E. K., Villalona, M. A., Hammond, L. A., Britten, C. D., Siu, L. L., et al. (2002). A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clinical Cancer Research, 8(7), 2142-2148.
119. Peart, M. J., Smyth, G. K., Van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., et al. (2005). Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proceedings of the National Academy of Sciences, USA, 102(10), 3697-3702.
120. Peira, E., Marzola, P., Podio, V., Aime, S., Sbarbati, A., & Gasco, M. R. (2003). In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. Journal of Drug Targeting, 11(1), 19-24.
121. Pellizzaro, C., Coradini, D., Morel, S., Ugazio, E., Gasco, M. R., & Daidone, M. G. (1999). Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery. Anticancer Research, 19(5B), 3921-3925.
122. Peoch, M., Farion, R., Hiou, A., Le Bas, J. F., Pasquier, B., & Remy, C. (2002). Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. Anticancer Research, 22(4), 2147-2151.
123. Petri, B., Bootz, A., Khalansky, A., Hekmatara, T., Muller, R., Uhl, R., et al. (2007). Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. Journal of Controlled Release, 117(1), 51-58.
124. Podio, V., Zara, G. P., Carazzonet, M., Cavalli, R., & Gasco, M. R. (2000a). Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats. The Journal of Pharmacy and Pharmacology, 52(9), 1057-1063.
125. Podio, V., Zara, G. P., Carazzonet, M., Cavalli, R., & Gasco, M. R. (2000b). Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats. The Journal of Pharmacy and Pharmacology, 52(9), 1057-1063.
126. Potmesil, M. (1994). Camptothecins: From bench research to hospital wards. Cancer Research, 54(6), 1431-1439.
127. Pouillart, P. R. (1998). Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Life Sciences, 63(20), 1739-1760.
128. Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002). Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacological Reviews, 54(4), 561-587.
129. Reddy, G. R., Bhojani, M. S., McConville, P., Moody, J., Moffat, B. A., Hall, D. E., et al. (2006). Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clinical Cancer Research, 12(22), 6677-6686.
130. Reid, T., Valone, F., Lipera, W., Irwin, D., Paroly, W., Natale, R., et al. (2004). Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer, 45(3), 381-386.
131. Rejman, J., Oberle, V., Zuhorn, I. S., & Hoekstra, D. (2004). Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. The Biochemical Journal, 377(Pt. 1), 159-169.
132. Rephaeli, A., Entin-Meer, M., Angel, D., Tarasenko, N., Gruss-Fischer, T., Bruachman, I., et al. (2006). The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Investigational New Drugs, 24(5), 383-392.
133. Rich, J. N., & Bigner, D. D. (2004). Development of novel targeted therapies in the treatment of malignant glioma. Nature Reviews. Drug Discovery, 3(5), 430-446.
134. Rong, Y., Durden, D. L., Van Meir, E. G., & Brat, D. J. (2006). 'Pseudopalisading' necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. Journal of Neuropathology Experimental Neurology, 65(6), 529-539.
135. Rosenstein, J. M., & Krum, J. M. (2004a). New roles for VEGF in nervous tissue-beyond blood vessels. Experimental Neurology, 187(2), 246-253.
136. Rosenstein, J. M., & Krum, J. M. (2004b). New roles for VEGF in nervous tissue-beyond blood vessels. Experimental Neurology, 187(2), 246-253.
137. Rowinsky, E. K., & Donehower, R. C. (1995). Paclitaxel (taxol). The New England Journal of Medicine, 332(15), 1004-1014.
138. Saleh, M., Stacker, S. A., & Wilks, A. F. (1996). Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Research, 56(2), 393-401.
139. Salomone, B., Ponti, R., Gasco, M. R., Ugazio, E., Quaglino, P., Osella-Abate, S., et al. (2000). In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid prodrug on melanoma cells: Evaluation of antiproliferative activity and apoptosis induction. Clinical & Experimental Metastasis, 18(8), 663-673.
140. Sanson, M. (2008). Editorial review: Targets for glioma treatment: From bench to bedside. Current Opinion in Oncology, 20(6), 650-651.
141. Sanson, M., Laigle-Donadey, F., & Benouaich-Amiel, A. (2006). Molecular changes in brain tumors: Prognostic and therapeutic impact. Current Opinion in Oncology, 18(6), 623-630.
142. Santini, V., Gozzini, A., Scappini, B., Grossi, A., & Rossi Ferrini, P. (2001). Searching for the magic bullet against cancer: The butyrate saga. Leukemia & Lymphoma, 42(3), 275-289.
143. Sathornsumetee, S., Rich, J. N., & Reardon, D. A. (2007). Diagnosis and treatment of high-grade astrocytoma. Neurologic Clinics, 25(4), 1111-1139, x.
144. Serganova, I., Doubrovin, M., Vider, J., Ponomarev, V., Soghomonyan, S., Beresten, T., et al. (2004). Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxiainducible factor-1 signal transduction activity in tumors in living mice. Cancer Research, 64(17), 6101-6108.
145. Serikawa, T., Kikuchi, A., Sugaya, S., Suzuki, N., Kikuchi, H., & Tanaka, K. (2006). In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy. Journal of Controlled Release, 113(3), 255-260.
146. Serpe, L., Guido, M., Canaparo, R., Muntoni, E., Cavalli, R., Panzanelli, P., et al. (2006). Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines. Journal of Nanoscience and Nanotechnology, 6(9-10), 3062-3069.
147. Serpe, L., Laurora, S., Pizzimenti, S., Ugazio, E., Ponti, R., Canaparo, R., et al. (2004). Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: Effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells. Anticancer Drugs, 15(5), 525-536.
148. Shenoy, V. S., Vijay, I. K., & Murthy, R. S. (2005). Tumour targeting: Biological factors and formulation advances in injectable lipid nanoparticles. The Journal of Pharmacy and Pharmacology, 57(4), 411-422.
149. Shin, J. S., & Abraham, S. N. (2001). Caveolae as portals of entry for microbes. Microbes and Infection, 3(9), 755-761.
150. Simons, K., & Ikonen, E. (1997). Functional rafts in cell membranes. Nature, 387(6633), 569-572.
151. Singal, P. K., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000). Adriamycin-induced heart failure: Mechanism and modulation. Molecular and Cellular Biochemistry, 207(1-2), 77-86.
152. Soldati, T., & Schliwa, M. (2006). Powering membrane traffic in endocytosis and recycling. Nature Reviews. Molecular Cell Biology, 7(12), 897-908.
153. Stan, A. C., Casares, S., Radu, D., Walter, G. F., & Brumeanu, T. D. (1999). Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer Research, 19(2A), 941-950.
154. Steiniger, S. C., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., et al. (2004). Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. International Journal of Cancer, 109(5), 759-767.
155. Stevens, P. J., Sekido, M., & Lee, R. J. (2004). A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharmaceutical Research, 21(12), 2153-2157.
156. Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318(5848), 287-290.
157. Stupp, R., Mason, W. P., Van Den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine, 352(10), 987-996.
158. Tan, C., De Noronha, R. G., Roecker, A. J., Pyrzynska, B., Khwaja, F., Zhang, Z., et al. (2005). Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Research, 65(2), 605-612.
159. Tiwari, S. B., & Amiji, M. M. (2006). A review of nanocarrierbased CNS delivery systems. Current Drug Delivery, 3(2), 219-232.
160. Toi, M., Matsumoto, T., & Bando, H. (2001). Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. The Lancet Oncology, 2(11), 667-673.
161. Tondelli, L., Ricca, A., Laus, M., Lelli, M., & Citro, G. (1998). Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Research, 26(23), 5425-5431.
162. Tsutsui, Y., Tomizawa, K., Nagita, M., Michiue, H., Nishiki, T., Ohmori, I., et al. (2007). Development of bionanocapsules targeting brain tumors. Journal of Controlled Release, 122(2), 159-164.
163. Ugazio, E., Marengo, E., Pellizzaro, C., Coradini, D., Peira, E., Daidone, M. G., et al. (2001). The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-H460 cell proliferation. European Journal of Pharmaceutics and Biopharmaceutics, 52(2), 197-202.
164. Vasir, J. K., & Labhasetwar, V. (2007). Biodegradable nanoparticles for cytosolic delivery of therapeutics. Advanced Drug Delivery Reviews, 59(8), 718-728.
165. Vijayaraghavalu, S., Raghavan, D., & Labhasetwar, V. (2007). Nanoparticles for delivery of chemotherapeutic agents to tumors. Current Opinion in Investigational Drugs, 8(6), 477-484.
166. Visone, R., Russo, L., Pallante, P., De Martino, I., Ferraro, A., Leone, V., et al. (2007). MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine-Related Cancer, 14(3), 791-798.
167. Von Holst, H., Knochenhauer, E., Blomgren, H., Collins, V. P., Ehn, L., Lindquist, M., et al. (1990). Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochirurgica (Wien), 104(1-2), 13-16.
168. Vredenburgh, J. J., Desjardins, A., Herndon, J. E., II, Marcello, J., Reardon, D. A., Quinn, J. A., et al. (2007). Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology, 25(30), 4722-4729.
169. Wall, M. E., Wani, M. C., Natschke, S. M., & Nicholas, A. W. (1986). Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from camptotheca acuminata decne: Total synthesis and biological activity. Journal of Medicinal Chemistry, 29(8), 1553-1555.
170. Wan, F., You, J., Sun, Y., Zhang, X. G., Cui, F. D., Du, Y. Z., et al. (2008). Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): Preparation and evaluation in vitro. International Journal of Pharmaceutics, 359(1-2), 104-110.
171. Wang, J. X., Sun, X., & Zhang, Z. R. (2002). Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 54(3), 285-290.
172. Wang, Y. X., Hussain, S. M., & Krestin, G. P. (2001). Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. European Radiology, 11(11), 2319-2331.
173. Williams, J., Lansdown, R., Sweitzer, R., Romanowski, M., LaBell, R., Ramaswami, R., et al. (2003). Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. Journal of Controlled Release, 91(1-2), 167-172.
174. Wissing, S. A., Kayser, O., & Muller, R. H. (2004). Solid lipid nanoparticles for parenteral drug delivery. Advanced Drug Delivery Reviews, 56(9), 1257-1272.
175. Wong, H. L., Bendayan, R., Rauth, A. M., Li, Y., & Wu, X. Y. (2007). Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Advanced Drug Delivery Reviews, 59(6), 491-504.
176. Wong, H. L., Bendayan, R., Rauth, A. M., &Wu, X. Y. (2004). Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. Journal of Pharmaceutical Sciences, 93(8), 1993-2008.
177. Wong, H. L., Bendayan, R., Rauth, A. M., Xue, H. Y., Babakhanian, K., & Wu, X. Y. (2006a). A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. The Journal of Pharmacology and Experimental Therapeutics, 317(3), 1372-1381.
178. Wong, H. L., Rauth, A. M., Bendayan, R., Manias, J. L., Ramaswamy, M., Liu, Z., et al. (2006b). A new polymerlipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharmaceutical Research, 23(7), 1574-1585.
179. Xu, H., Lv, M., & Tian, X. (2009). A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Current Medicinal Chemistry, 16(3), 327-349.
180. Xu, Z., Gu, W., Huang, J., Sui, H., Zhou, Z., Yang, Y., et al. (2005). In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. International Journal of Pharmaceutics, 288(2), 361-368.
181. Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., & Yang, C. Z. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. Journal of Controlled Release, 59(3), 299-307.
182. Yang, W., Barth, R. F., Wu, G., Kawabata, S., Sferra, T. J., Bandyopadhyaya, A. K., et al. (2006a). Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clinical Cancer Research, 12(12), 3792-3802.
183. Yang, W., Barth, R. F., Wu, G., Kawabata, S., Sferra, T. J., Bandyopadhyaya, A. K., et al. (2006b). Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clinical Cancer Research, 12(12), 3792-3802.
184. Yang, W., Wu, G., Barth, R. F., Swindall, M. R., Bandyopadhyaya, A. K., Tjarks, W., et al. (2008). Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clinical Cancer Research, 14(3), 883-891.
185. Yano, A., Shingo, T., Takeuchi, A., Yasuhara, T., Kobayashi, K., Takahashi, K., et al. (2005). Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia. Journal of Neurosurgery, 103(1), 104-114.
186. Yasuhara, T., Shingo, T., Muraoka, K., wen Ji, Y., Kameda, M., Takeuchi, A., et al. (2005). The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo parkinson's disease model. Brain Research, 1038(1), 1-10.
187. Zara, G. P., Bargoni, A., Cavalli, R., Fundaro, A., Vighetto, D., & Gasco, M. R. (2002a). Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. Journal of Pharmaceutical Sciences, 91(5), 1324-1333.
188. Zara, G. P., Cavalli, R., Bargoni, A., Fundaro, A., Vighetto, D., & Gasco, M. R. (2002b). Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxorubicin in brain and other tissues. Journal of Drug Targeting, 10(4), 327-335.
189. Zara, G. P., Cavalli, R., Fundaro, A., Bargoni, A., Caputo, O., & Gasco, M. R. (1999). Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacological Research, 40(3), 281-286.
190. Zhang, Y., Jeong Lee, H., Boado, R. J., & Pardridge, W. M. (2002). Receptor-mediated delivery of an antisense gene to human brain cancer cells. The Journal of Gene Medicine, 4(2), 183-194.
191. Zhang, Y., Zhang, Y. F., Bryant, J., Charles, A., Boado, R. J., & Pardridge, W. M. (2004). Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clinical Cancer Research, 10(11), 3667-3677.
192. Zhou, Y. H., Tan, F., Hess, K. R., & Yung, W. K. (2003). The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: Relationship to tumor grade and survival. Clinical Cancer Research, 9(9), 3369-3375.